Neuren Pharmaceuticals (ASX:NEU) announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome. Significant improvement was observed by both clinicians and caregivers from treatment | ASX announcement: https://www.neurenpharma.com/pdf/f9ca13b8-b75f-4ff5-a5b7-1dcb75d547d6/P2-trial-shows-significant-improvements-in-PhelanMcDermid.pdf #shorts
88E
0.002
100%
OB1
0.001
-50%
BUY
0.004
100%
H2G
0.003
-25%
CR9
0.004
100%
WYX
0.03
-23.1%
AYT
0.005
66.7%
SLH
1.54
-22.2%
WOA
0.026
62.5%
IMI
0.011
-21.4%
ASR
0.003
50%
RML
0.011
-21.4%
SCP
0.19
46.2%
NAE
0.004
-20%
VAR
0.009
28.6%
RNX
0.004
-20%
BCC
0.099
25.3%
HE8
0.013
-18.8%
ADG
0.005
25%
BCB
0.005
-16.7%
MVL
0.01
25%
EPM
0.005
-16.7%
WSR
0.01
25%
HOR
0.015
-16.7%
ETM
0.087
22.5%
REC
0.015
-16.7%
FAL
0.12
21.2%
WC1
0.015
-16.7%
AKN
0.006
20%
CHR
0.042
-16%
YAR
0.006
20%
CYM
0.017
-15%
MHK
0.425
19.7%
GEN
0.034
-15%
MAUCA
1.2
19.4%
CVR
0.175
-14.6%
BSX
0.074
19.4%
IPB
0.006
-14.3%
VMC
0.11
18.3%
PWN
0.012
-14.3%
